Depo-Provera Pilot Lawsuit Deadlines in MDL Extended Approximately 6 Weeks

Lawsuits over brain tumors from Depo-Provera are being coordinated between the federal MDL and state court proceedings in Delaware and New York, to streamline discovery and avoid inconsistent pretrial schedules.

The U.S. District Judge overseeing all federal Depo-Provera brain tumor lawsuits has granted a request by the parties for additional time to complete general causation work for several “pilot” cases being prepared for trial early next year, as part of a coordinated effort to align deadlines and pretrial proceedings with similar cases moving forward in various different state courts.

In product liability litigation, general causation refers to the strength of evidence that establishes whether a drug or medical device is capable of causing the type of injury alleged in lawsuits, such as whether Depo-Provera can cause meningioma brain tumors, as a growing number of women nationwide now claim.

Nearly 2,000 Women Claim Depo-Provera Caused Brain Tumors

At the center of the litigation is Depo-Provera, a long-acting birth control injection that has been marketed by Pfizer for more than three decades. The shot is administered four times per year to prevent pregnancy, and has been used by more than 70 million women worldwide, based on the belief that it carried few side effects.

However, concerns over the birth control shot’s safety emerged last year, after studies linked Depo-Provera to an increased risk of intracranial meningioma, suggesting that women who received the injections may be 5.5 times more likely to develop this type of brain tumor. Meningiomas can lead to serious, potentially life-threatening complications, often requiring ongoing medical monitoring or surgical removal.

In response to the findings, Pfizer and several generic manufacturers now face more than 1,453 lawsuits filed in federal courts nationwide, with hundreds of additional claims also pending in Delaware and New York state courts.

Given common questions of fact and law raised in complaints brought by women nationwide, the federal litigation has been consolidated for coordinated discovery and pretrial proceedings in an MDL (multidistrict litigation), which is pending before U.S. District Judge M. Casey Rodgers in the Northern District of Florida. However, there are also lawsuits involving at least 78 plaintiffs pending before Judge Sabrina Kraus in New York state court, and 10 cases involving 332 plaintiffs in Delaware, pending before Judge Kathleen M. Vavala.

At the federal level, Judge Rodgers has called for the parties to prepare five Depo-Provera “pilot” lawsuits for early test trials, which will give the parties the opportunity to see how juries respond to evidence and testimony likely to be repeated throughout the litigation. Last month, she also agreed to coordinate the litigation with the Delaware and New York state courts.

As part of the process of preparing those claims for trial, the plaintiffs must first show that it is scientifically feasible that Depo-Provera can cause the development of brain tumors, which is known as general causation.

On October 24, Judge Rodgers met with representatives of plaintiffs, defendants and the state courts as part of a case management conference. During the conference, the parties requested that the general causation process be extended by six more weeks, in order to sync up with the process in the Delaware and New York courts, according to a case management order (PDF).

Lawyers further argued that additional time will also give the parties the ability to “address length of product use and length of time between product use and injury, which may impact causality.”

Judge Rodgers issued an amended scheduling order (PDF) on October 30, giving the parties six additional weeks to finish general causation. The updated schedule calls for plaintiffs’ general causation expert disclosures by December 1, and defendants’ expert disclosures by January 9, 2026. It also sets the deadline for deposition of all general causation experts for February 20, 2026, and the filing of any Rule 702 motions challenging the admissibility of general causation expert testimony by March 22.

If the plaintiffs establish that there is sufficient evidence for a jury to find general causation between Depo-Provera and meningioma brain tumors, the litigation will proceed to the pilot trials. While the outcomes of these early trial dates will not be binding on other claims in the federal or state courts, they could be helpful in forming the basis of a Depo-Provera lawsuit settlement agreement to avoid the need for hundreds of individual trials to be scheduled nationwide.

To stay up to date on this litigation, sign up to receive Depo-Provera lawsuit updates sent directly to your inbox.